Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing

Hui Yu, Victor Wei Zhang, Asbjørg Stray-Pedersen, Imelda Celine Hanson, Lisa R. Forbes, M. Teresa de la Morena, Ivan K. Chinn, Elizabeth Gorman, Nancy J. Mendelsohn, Tamara Pozos, Wojciech Wiszniewski, Sarah K. Nicholas, Anne B. Yates, Lindsey E. Moore, Knut Erik Berge, Hanne Sorte, Diana K. Bayer, Daifulah ALZahrani, Raif S. Geha, Yanming FengGuoli Wang, Jordan S. Orange, James R. Lupski, Jing Wang, Lee Jun Wong

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Background Primary immunodeficiency diseases (PIDDs) are inherited disorders of the immune system. The most severe form, severe combined immunodeficiency (SCID), presents with profound deficiencies of T cells, B cells, or both at birth. If not treated promptly, affected patients usually do not live beyond infancy because of infections. Genetic heterogeneity of SCID frequently delays the diagnosis; a specific diagnosis is crucial for life-saving treatment and optimal management. Objective We developed a next-generation sequencing (NGS)–based multigene-targeted panel for SCID and other severe PIDDs requiring rapid therapeutic actions in a clinical laboratory setting. Methods The target gene capture/NGS assay provides an average read depth of approximately 1000×. The deep coverage facilitates simultaneous detection of single nucleotide variants and exonic copy number variants in one comprehensive assessment. Exons with insufficient coverage (<20× read depth) or high sequence homology (pseudogenes) are complemented by amplicon-based sequencing with specific primers to ensure 100% coverage of all targeted regions. Results Analysis of 20 patient samples with low T-cell receptor excision circle numbers on newborn screening or a positive family history or clinical suspicion of SCID or other severe PIDD identified deleterious mutations in 14 of them. Identified pathogenic variants included both single nucleotide variants and exonic copy number variants, such as hemizygous nonsense, frameshift, and missense changes in IL2RG; compound heterozygous changes in ATM, RAG1, and CIITA; homozygous changes in DCLRE1C and IL7R; and a heterozygous nonsense mutation in CHD7. Conclusion High-throughput deep sequencing analysis with complete clinical validation greatly increases the diagnostic yield of severe primary immunodeficiency. Establishing a molecular diagnosis enables early immune reconstitution through prompt therapeutic intervention and guides management for improved long-term quality of life.

Original languageEnglish (US)
Pages (from-to)1142-1151.e2
JournalJournal of Allergy and Clinical Immunology
Volume138
Issue number4
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

    Fingerprint

Keywords

  • molecular diagnostics
  • next-generation sequencing
  • Severe combined immunodeficiency
  • severe combined immunodeficiency newborn screening

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Yu, H., Zhang, V. W., Stray-Pedersen, A., Hanson, I. C., Forbes, L. R., de la Morena, M. T., Chinn, I. K., Gorman, E., Mendelsohn, N. J., Pozos, T., Wiszniewski, W., Nicholas, S. K., Yates, A. B., Moore, L. E., Berge, K. E., Sorte, H., Bayer, D. K., ALZahrani, D., Geha, R. S., ... Wong, L. J. (2016). Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing. Journal of Allergy and Clinical Immunology, 138(4), 1142-1151.e2. https://doi.org/10.1016/j.jaci.2016.05.035